Skip to content
6-K

Foreign Interim / Material

Scinai Immunotherapeutics Ltd. SCNI

0001213900-25-083373

← back to feed
Filed
Sep 2, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q2 2025 · Jun 30, 2025 6.36B sh
Shares Diluted Q2 2025 · Jun 30, 2024 2.29B sh
Capex Q2 2025 · Jun 30, 2025 $12K
Capex Q2 2025 · Jun 30, 2024 $8K
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$2.58M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$3.22M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $989K
Cash And Equivalents Q2 2025 · Dec 31, 2024 $1.96M
Cash And Equivalents Q2 2025 · Jun 30, 2024 $3.08M
Stockholders Equity Q2 2025 · Jun 30, 2025 $7.86M
Stockholders Equity Q2 2025 · Dec 31, 2024 $9.98M
Stockholders Equity Q2 2025 · Jun 30, 2024 −$7.28M
Stockholders Equity Q2 2025 · Dec 31, 2023 −$4.57M
Current Liabilities Q2 2025 · Jun 30, 2025 $2.12M
Current Liabilities Q2 2025 · Dec 31, 2024 $1.81M
Current Assets Q2 2025 · Jun 30, 2025 $1.51M
Current Assets Q2 2025 · Dec 31, 2024 $2.39M
Total Assets Q2 2025 · Jun 30, 2025 $11.84M
Total Assets Q2 2025 · Dec 31, 2024 $13.45M
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.00
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.00
Eps Basic Q2 2025 · Jun 30, 2025 −$0.00
Eps Basic Q2 2025 · Jun 30, 2024 −$0.00
Sga Expense Q2 2025 · Jun 30, 2025 $1.26M
Sga Expense Q2 2025 · Jun 30, 2024 $1M
Rd Expense Q2 2025 · Jun 30, 2025 $1.24M
Rd Expense Q2 2025 · Jun 30, 2024 $2.79M
Net Income Q2 2025 · Jun 30, 2025 −$4.13M
Net Income Q2 2025 · Jun 30, 2024 −$4.48M
Operating Income Q2 2025 · Jun 30, 2025 −$3.76M
Operating Income Q2 2025 · Jun 30, 2024 −$3.96M
Gross Profit Q2 2025 · Jun 30, 2025 −$1.27M
Gross Profit Q2 2025 · Jun 30, 2024 −$164K
Cost Of Revenue Q2 2025 · Jun 30, 2025 $2.04M
Cost Of Revenue Q2 2025 · Jun 30, 2024 $448K
Revenue Q2 2025 · Jun 30, 2025 $773K
Revenue Q2 2025 · Jun 30, 2024 $284K